Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merrimack Pharmaceuticals Inc. (MACK)
NASDAQ:MACK
Merrimack Pharmaceuticals (MACK) Stock Price & Analysis
354 Followers
MACK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.53 - $15.89
Previous Close$15.03
Volume187.59K
Average Volume (3M)141.71K
Market Cap
$218.41M
Enterprise Value$199.54M
Total Cash (Recent Filing)$18.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-182.0
Beta1.84
Next EarningsN/A
EPS EstimateN/A
Last Dividend Ex-Date
Dec 13, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding14,516,170
10 Day Avg. Volume120,457
30 Day Avg. Volume141,714
Standard Deviation0.32
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)11.60
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-181.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-191.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Merrimack Pharmaceuticals News
PremiumCompany Announcements
Merrimack Pharmaceuticals Announces Nasdaq Delisting and Liquidation Plan
PremiumCompany Announcements
Merrimack’s FDA Approval Milestone and Scheduled Dissolution Vote
PremiumCompany Announcements
Merrimack Pharmaceuticals Proposes Liquidation Plan
PremiumCompany Announcements
Merrimack Pharmaceuticals Weighs Dissolution Post FDA ApprovalOwnership Overview
74.52% Insiders
8.88% Mutual Funds
10.32% Other Institutional Investors
6.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MACK FAQ
What was Merrimack Pharmaceuticals Inc.’s price range in the past 12 months?
Merrimack Pharmaceuticals Inc. lowest stock price was $11.53 and its highest was $15.89 in the past 12 months.
What is Merrimack Pharmaceuticals Inc.’s market cap?
Currently, no data Available
When is Merrimack Pharmaceuticals Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Merrimack Pharmaceuticals Inc.’s earnings last quarter?
Currently, no data Available
Is Merrimack Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Merrimack Pharmaceuticals Inc.’s price is currently Overvalued.
Does Merrimack Pharmaceuticals Inc. pay dividends?
Merrimack Pharmaceuticals Inc. pays a Notavailable dividend of $0.5 which represents an annual dividend yield of N/A. See more information on Merrimack Pharmaceuticals Inc. dividends here
What is Merrimack Pharmaceuticals Inc.’s EPS estimate?
Merrimack Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Merrimack Pharmaceuticals Inc. have?
Merrimack Pharmaceuticals Inc. has 14,531,760 shares outstanding.
What happened to Merrimack Pharmaceuticals Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Merrimack Pharmaceuticals Inc.?
Among the largest hedge funds holding Merrimack Pharmaceuticals Inc.’s share is Western Standard Llc. It holds Merrimack Pharmaceuticals Inc.’s shares valued at 29M.
---
Merrimack Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 278.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.51%
12-Months-Change
Fundamentals
Return on Equity
-6.22%
Trailing 12-Months
Asset Growth
-3.27%
Trailing 12-Months
Company Description
Merrimack Pharmaceuticals Inc.
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
---
Technical Analysis
---